prikaz prve stranice dokumenta IZRAŽAJ GLIKOPROTEINA GP96 I LIMFOCITNIH SUBPOPULACIJA U RAZLIČITIM IMUNOFENOTIPOVIMA KARCINOMA DOJKE
Access restricted to students and staff of home institution
doctoral thesis
IZRAŽAJ GLIKOPROTEINA GP96 I LIMFOCITNIH SUBPOPULACIJA U RAZLIČITIM IMUNOFENOTIPOVIMA KARCINOMA DOJKE
Rijeka: University of Rijeka, Faculty of Medicine, 2019. urn:nbn:hr:184:960402
Radolović, Petra
University of Rijeka
Faculty of Medicine
Department of Surgery

Cite this document

Radolović, P. (2019). IZRAŽAJ GLIKOPROTEINA GP96 I LIMFOCITNIH SUBPOPULACIJA U RAZLIČITIM IMUNOFENOTIPOVIMA KARCINOMA DOJKE (Doctoral thesis). Rijeka: University of Rijeka, Faculty of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:184:960402

Radolović, Petra. "IZRAŽAJ GLIKOPROTEINA GP96 I LIMFOCITNIH SUBPOPULACIJA U RAZLIČITIM IMUNOFENOTIPOVIMA KARCINOMA DOJKE." Doctoral thesis, University of Rijeka, Faculty of Medicine, 2019. https://urn.nsk.hr/urn:nbn:hr:184:960402

Radolović, Petra. "IZRAŽAJ GLIKOPROTEINA GP96 I LIMFOCITNIH SUBPOPULACIJA U RAZLIČITIM IMUNOFENOTIPOVIMA KARCINOMA DOJKE." Doctoral thesis, University of Rijeka, Faculty of Medicine, 2019. https://urn.nsk.hr/urn:nbn:hr:184:960402

Radolović, P. (2019). 'IZRAŽAJ GLIKOPROTEINA GP96 I LIMFOCITNIH SUBPOPULACIJA U RAZLIČITIM IMUNOFENOTIPOVIMA KARCINOMA DOJKE', Doctoral thesis, University of Rijeka, Faculty of Medicine, accessed 18 April 2024, https://urn.nsk.hr/urn:nbn:hr:184:960402

Radolović P. IZRAŽAJ GLIKOPROTEINA GP96 I LIMFOCITNIH SUBPOPULACIJA U RAZLIČITIM IMUNOFENOTIPOVIMA KARCINOMA DOJKE [Doctoral thesis]. Rijeka: University of Rijeka, Faculty of Medicine; 2019 [cited 2024 April 18] Available at: https://urn.nsk.hr/urn:nbn:hr:184:960402

P. Radolović, "IZRAŽAJ GLIKOPROTEINA GP96 I LIMFOCITNIH SUBPOPULACIJA U RAZLIČITIM IMUNOFENOTIPOVIMA KARCINOMA DOJKE", Doctoral thesis, University of Rijeka, Faculty of Medicine, Rijeka, 2019. Available at: https://urn.nsk.hr/urn:nbn:hr:184:960402

Please login to the repository to save this object to your list.
Metadata
TitleIZRAŽAJ GLIKOPROTEINA GP96 I LIMFOCITNIH SUBPOPULACIJA U RAZLIČITIM IMUNOFENOTIPOVIMA KARCINOMA DOJKE
Title (english)EXPRESSION OF GLYCOPROTEIN GP96 AND LYMPHOCYTIC SUBPOPULATIONS IN VARIOUS IMMUNOPHENOTYPES OF BREAST CARCINOMA
AuthorPetra Radolović
MentorDamir Grebić (mentor)
MentorElvira Mustać (komentor)
Committee memberHrvoje Jakovac (predsjednik povjerenstva)
Committee memberSnježana Tomić (član povjerenstva)
Committee memberIngrid Belac-Lovasić (član povjerenstva)
Committee memberDamir Grebić (član povjerenstva)
Committee memberElvira Mustać (član povjerenstva)
GranterUniversity of Rijeka
Faculty of Medicine
(Department of Surgery)
Rijeka
Defense date and country2019-11-19, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Surgery
Universal decimal classification
(UDC)		617 - Surgery. Orthopaedics. Ophthalmology
Thesaurus
(MESH - Medical Subject Headings)
Abstract
Cilj istraživanja: Karcinom dojke pokazuje iznimnu kliničku i molekularnu heterogenost. Prekomjerna ekspresija glikoproteina gp96 smatra se negativnim prognostičkim i prediktivnim čimbenikom u karcinomu dojke. Prognostička uloga tumorskog limfocitnog infiltrata je kontroverzna. Svrha ovog istraživanja je prikazati razlike u ekspresiji gp96 i CD4+ i CD8+ T-limfocita u svim imunohistokemijskim skupinama karcinoma dojke te ih usporediti sa kliničkim podacima vezanim uz tijek i ishod bolesti. Materijali i Metode: Proveli smo retrospektivno opservacijsko istraživanje obradom i analizom 152 bioptička uzorka bolesnica koji su prethodno imunohistokemijski klasificirani. Nakon imunohistokemijske obrade, uzorci su analizirani mikroskopski (Olympus BX41 Microscope, CeLL A sustav za obradu slika) te su pozitivne stanice ručno brojane u sva tri reza pojedine biopsije za svaku bolesnicu. Rezultate smo usporedili sa kliničkim podacima (dob bolesnica, pozitivni aksilarni limfni čvorovi na početku liječenja, pojava lokalnog recidiva i udaljenih metastaza i smrtni ishod) iz medicinske baze podataka. Rezultati: U skupini bolesnica sa trostruko negativnim karcinomom, dokazali smo značajno veću ekspresiju CD4+ stanica u bolesnica kod kojih nije zabilježena pojava lokalnog recidiva kao i značajnu korelaciju između manje ekspresije CD4+ stanica i smrtnog ishoda. U skupini bolesnica sa Luminal B HER2+ karcinomom, dokazali smo značajno veći udio CD8+ stanica u ukupnom imunološkom infiltratu u bolesnica sa pojavom lokalnog recidiva. Najveću ekspresiju gp96 dokazali smo u bolesnica sa trostruko negativnim karcinomom, najmanju u bolesnica sa Luminal A i Luminal B HER2- karcinomom. Zaključak: Ovo je istraživanje dokazalo značajno veću ekspresiju gp96 i gušći tumorski limfocitni infiltrat u malignijim tipovima karcinoma dojke i predstavlja važni doprinos u afirmaciji prognostičke uloge ispitivanih varijabli. Otkrili smo oprečnu prognostičku važnost CD4+ i CD8+ T-limfocita u različitim tipovima karcinoma dojke.
Abstract (english)
Aims: Breast carcinoma shows extensive clinical and molecular heterogenecity. Glycoprotein gp96 is considered a negative prognostic and predictive factor. Controversy exists over the prognostic role of tumor lymphocytic infiltrates. Goal of this study is to illustrate differences in gp96 and CD4+ and CD8+ T- lymphocytes expression among all immunohistochemical groups of breast carcinoma in relation to the clinical course and outcome of the disease. Material and Methods: A retrospective observational study was conducted through processing and analysis of 152 female patient tissue samples wich were previously immunohistochemically classified. After immunohistochemical processing, the samples were microscopically analysed (Olympus BX41 Microscope, CeLL A image processing system) and positive cells were manually calculated in entire biopsy sample for each patient. Results: In the group of patients with triple negative carcinoma, a significantly higher number of CD4 positive cells in patients with no local recurrence was proven, as well as a significant correlation between a smaller number of CD4 positive cells with a lethal outcome. In the group of patients with Luminal B HER2 + carcinoma, a significantly higher proportion of CD8 + cells in patients with local recurrence was demonstrated. The highest glycoprotein gp96 expression was demonstrated in the group of patients with triple negative carcinoma, the lowest in patients with Luminal A and Luminal B HER2-carcinoma. Conclusion: This study has shown significantly higher gp96 expression and higher extent of tumor lymphocytic infiltrate in more malignant types of breast carcinoma and represents a significant contribution in affirmation of prognostic role of these variables. We discovered different prognostic importance of CD4+ and CD8+ T-lymphocytes in various types of breast carcinoma.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:184:960402
Study programmeTitle: Biomedicine Postgraduate (doctoral) study programme
Study programme type: university
Study level: postgraduate
Academic / professional title: doktor/doktorica znanosti, područje biomedicine i zdravstvo (doktor/doktorica znanosti, područje biomedicine i zdravstvo)
Type of resourceText
File originBorn digital
Access conditionsAccess restricted to students and staff of home institution
Terms of useLicence In copyright icon
RepositoryRepository of the University of Rijeka, Faculty of Medicine
Created on2020-02-21 07:58:02

(©) Nacionalna i sveučilišna knjižnica u Zagrebu 2015. Sva prava pridržana. | Hrvatske bratske zajednice 4 p.p. 550, 10000 Zagreb, Hrvatska Tel. ++ 385 1 616-4040
OIB: 84838770814 | IBAN: HR66 2340 0091 1000 1008 1, Porezni broj (PDV identifikacijski broj) - VAT Number: HR84838770814
Prijava u repozitorij